Krenar Komoni

LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control

 Editor Nico Saraceno spoke with several key opinion leaders about how technology, innovation, and inclusivity are reshaping pharmaceutical logistics.

Krenar Komoni, founder and CEO of Tive, highlighted a critical industry shift: the move from passive to real-time temperature control. While adoption has been slower than anticipated, Komoni noted that progress is accelerating, aided by new technologies. He predicted that the full transition to real-time visibility could take another 12 to 36 months, citing the challenges of scaling across global networks.

McKesson’s Ammie McAsey, SVP of supply chain operations, discussed how advanced therapies are challenging traditional distribution models. Precision medicines and individualized treatments require a new level of quality assurance and communication across stakeholders. McAsey emphasized investments in both physical infrastructure, including refrigeration, frozen, and cryogenic systems, and digital platforms that enable seamless communication between providers and manufacturers. As she explained, distributors like McKesson play a key role in bridging these operational and technological gaps.

Finally, healthcare supply chain expert Dave Malenfant reflected on LogiPharma’s evolution over the past two decades, noting the conference’s growing inclusivity and representation. Once a male-dominated space, today’s event features diverse voices and a mix of companies spanning clinical and commercial supply chain disciplines.

Together, these insights underscore a unifying theme: pharma supply chains are becoming more connected, data-driven, and people-focused than ever before.

A transcript of their conversation of their conversation can be found below.

 Welcome to a special edition of LogiPharma USA coverage. I’m Nico Saraceno, editor of 

. This year’s installment of the conference was yet another action-packed one, as I had the opportunity to speak with a variety of KOLs in the space, including Krenar Komoni, founder and CEO of Tive, who highlighted the transition in pharma from passive to real-time temperature control.

How did he do that? He noted delays in tech adoption while emphasizing how AI and automation will soon drive cost savings, improved quality, and stronger customer experience.

 What challenges are currently impacting the temperature-controlled space?

 So the temperature control space and all the various companies, especially in the pharmaceutical side, they're going through a transition phase, which I call it, going from passive to real time. And it's taking its time. And I wish we were there sooner, but there's a lot of reasons why we're not there yet.

Technology providers haven't moved as fast we're finally just for instance, with dive, we released a solo pro device, which is a pharma specific real time tracker that meets all the 21 CFR Part 11 requirements. It's GXP compliant. And to be able to move everything from passive to real time, it's gonna take a little bit longer time. Call it another 12 months, maybe 24 to 36 months max. But this is one of the challenges right now, is this transition, and what comes with this transition.

Now when I asked Ammie McAsey, McKesson’s SVP of Supply Chain Ops, how advanced therapies are challenging traditional supply chain models, she dove into the need for end-to-end visibility among other qualities.

 Challenging the traditional supply chain model, traditional kind of pharma has been—in the distributor space—built for speed and efficiency, and while that's critically important, quality is of the utmost importance. The supply chain seems to be a little bit longer and has a lot more partners as we think about the precision medicine, and potentially one therapy for one cure and one patient.

The investment in technology to ensure end-to-end visibility and end-to-end communication is really, really important, so that's challenging the model. There are also temperature challenges, vibration challenges, multiple other scenarios that we have to account for with these specialized drugs.

How are we addressing that? Really around investments, and we have to look again across the supply chain for those investments, whether it's in refrigeration, in frozen, in cryo, or whether it's digital investments that allow for that visibility and tracking and communication between the provider, as well as the manufacturer of the drug or the therapy. You have to hit it from both angles, but I think as we sit in the middle as a distributor, we're well positioned to do both.

 Let us not forget Dave Malenfant, a healthcare supply chain expert, who took us through LogiPharma USA’s development over the past two decades.

 When LogiPharma first came out, there were not a lot of women, and it was a very male dominated industry. And we've evolved where, if you notice the crowd now, a lot of women. Finally, we've got a lot of women that are coming into the industry, WBR and LogiPharma has done a really good job of trying to embrace as many different companies, small, medium, large, and in folks that are really concentrated on both the clinical side and on the commercial side of supply chain.

Videos

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

LogiPharma USA 2025: What Topics Do You Think Will headline the 25th LogiPharma USA?

In a recent panel discussion on supply chain security, Krenar Komoni emphasized the growing importance of collaboration among vendors, logistics providers, and technology companies to combat evolving threats in the industry. The conversation highlighted two main types of theft impacting the supply chain: direct theft, where goods are physically stolen from trailers or containers, and strategic theft, a more sophisticated form involving social engineering tactics where fake carriers impersonate legitimate ones to intercept shipments.

To address these risks, panelists discussed a multi-layered security approach. Tools like carrier vetting software, GPS trackers, seals, and even armed escorts were identified as part of a tiered defense system. Komoni stressed that no single solution can fully secure a supply chain; rather, companies must integrate multiple protective measures into their operations to build resilience.

A major highlight of the discussion was the shift in the pharmaceutical industry from passive monitoring to real-time tracking, accelerated by new technologies like the Solo Pro device. This transition enhances visibility and responsiveness in managing high-value or sensitive shipments.The panel also explored how closer partnerships between logistics providers, shippers, and tech firms are strengthening the supply chain. This “triangle” of collaboration allows for better implementation and use of advanced technologies, increasing trust and efficiency across the board.

Looking ahead, Komoni noted that AI and automation will play a larger role in supply chain security, helping to predict threats and streamline operations in a rapidly evolving environment. The session concluded with a clear takeaway: securing the supply chain requires continuous adaptation, strong relationships, and layered, technology-driven solutions.

A transcript of Komoni’s conversation with 

What topics do you think will headline the 25th LogiPharma USA?

 I really believe the topic that we're going to continue to discuss is around how AI is infiltrated into our businesses, and how it's helping us run supply chains better, especially helping companies automate their supply chains today, I don't know if it feels only for me, but I believe the world's moving very fast, and the speed at which is accelerating, like the concept of singularity, everything is moving to an exponential pace at speed.

If you look at where open AI and ChatGPT were a year ago compared to 24 months ago, there's been tremendous amount of progress, and that progress is so much faster and better a month from now, but pharma moves a little slow because of regulatory requirements, which is a good thing, because these are medicines that are going in our bodies are in life saving, but it's going to have a put a lot of pressure on companies to innovate and innovate quicker than they have. 

I believe five years from now, even three years from now, four years from now, this is a topic we're going to continue to discuss. And I believe it's a challenge on its own, but I'm very excited to be part of people who are going to help pharmaceutical companies tackle it.

Articles

Collaboration among vendors, logistics providers, and technology companies is crucial to counteract supply chain threats, including direct and strategic theft. A multi-layered security approach, integrating tools like carrier vetting software and GPS trackers, is essential for resilience. The pharmaceutical industry is shifting from passive monitoring to real-time tracking, enhancing shipment management. Strong partnerships within the supply chain "triangle" improve technology implementation and efficiency. AI and automation are expected to play a significant role in future supply chain security, necessitating continuous adaptation and innovation.

Krenar Komoni, founder and CEO of Tive, predicts that AI-driven automation and its accelerating impact on pharmaceutical supply chains will remain a headline topic at LogiPharma USA, as the industry faces growing pressure to innovate while balancing strict regulatory requirements.

LogiPharma USA 2025: What Topics Do You Think Will Headline the 25th LogiPharma USA?

LogiPharma USA 2025: Challenges Currently Impacting the Temperature-Controlled Space

In a recent panel discussion on supply chain security, Krenar Komoni, founder and CEO of Tive, emphasized the growing importance of collaboration among vendors, logistics providers, and technology companies to combat evolving threats in the industry. The conversation highlighted two main types of theft impacting the supply chain: direct theft, where goods are physically stolen from trailers or containers, and strategic theft, a more sophisticated form involving social engineering tactics where fake carriers impersonate legitimate ones to intercept shipments.

What challenges are currently impacting the temperature-controlled space?

 So the temperature control space and all the various companies, especially in the pharmaceutical side, they're going through a transition phase, which I call it, going from passive to real time. And it's taking its time. And I wish we were there sooner, but there's a lot of reasons why we're not there yet. Technology providers haven't moved as fast we're finally just for instance, with dive, we released a solo pro device, which is a pharma specific real time tracker that meets all the 21 CFR Part 11 requirements. It's GXP compliant. And to be able to move everything from passive to real time, it's gonna take a little bit longer time. Call it another 12 months, maybe 24 to 36 months max. But this is one of the challenges right now, is this transition, and what comes with this transition as everything becomes more real time. Now, various workflow automations that need to be in place suddenly can actually work. And with AI and these workflow automations, customers are going to be able to get benefit from the real time data and see their costs go down, their quality go up, and customer experience improve.

Krenar Komoni, founder and CEO of Tive, highlights the transition in pharma from passive to real-time temperature control, noting delays in technology adoption but emphasizing how AI and automation will soon drive cost savings, improved quality, and stronger customer experience.

LogiPharma USA 2025: How The Pharmaceutical Industry Collaborates to Boost Resilience Across The Global Supply Network

 How is the industry collaborating in order to help ensure that there is a boost in resilience across the global supply network?

 I think one area that we really see the close collaboration is logistics service providers working very closely with shippers, which they've always have, but they've started to really work very closely with technology providers like Tive, and we've seen that triangle become stronger than ever before, and the reason is because they're seeing that if a logistics service provider starts to embrace the technology and actually start utilizing that technology, they can help the shipper, and the shipper can build higher trust with logistics service provider, and the technology providers can provide that technology to the logistics service provider, but the shipper gets the benefit. 

So this triangle is becoming really strong, and that collaboration, I believe it just enhances the overall industry, and makes for better experience for everybody. One thing that Chuck mentioned, which was really interesting, is like security is not a revenue-generating business, right? Or a thought like security is something you have to do, you want to do, and you want to look at various costs. And every layer that I mentioned has its own costs associated with it. But if you can start, like I said, with free where you build the trust and the relationship with all your vendors, all your logistics service providers, and then you keep adding lower cost things first, and then continue to see to at least make it more difficult for everybody to penetrate to your supply chain.

Krenar Komoni, founder and CEO of Tive, explains how the pharmaceutical industry’s transition from passive to real-time temperature control creates short-term challenges but will ultimately enable AI-driven automation, lower costs, higher quality, and better customer experiences.